Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Taeeumjowui-tang (also known as Taeumjowi-tang or TJT) is a traditional Korean herbal formulation originating from Sasang constitutional medicine. It consists of eight herbs and was first documented in the classic text "Donguisusebowon" by Lee Je-ma. Traditionally, it is prescribed for individuals classified as the Taeum type to treat stomach-related symptoms but has become widely used for obesity management and related metabolic disorders in Korea. Clinical studies and animal models have shown that Taeeumjowui-tang exerts anti-obesity effects, improves lipid profiles, and may also benefit atopic dermatitis (AD), especially when these conditions are comorbid. Mechanistically, it acts by downregulating inflammatory pathways including nuclear factor-kappa B (NF-κB), mitogen-activated protein kinases (MAPKs such as ERK, JNK, p38), and hypoxia-inducible factor 1 alpha (HIF-1α). These actions result in reduced inflammation markers such as interleukin-4 (IL-4), IL-6, tumor necrosis factor-alpha (TNF-α), immunoglobulin E levels, epidermal thickness, eosinophil/mast cell infiltration in skin lesions associated with AD and obesity[1][2][3][5][7]. It is most commonly administered orally.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on taeeumjowui-tang.